Reduced intensity conditioning is effective for hematopoietic SCT in dyskeratosis congenita-related BM failure

Bone Marrow Transplantation

Volumn 48, Issue 9, 2013, Pages 1168-1172

  Ayas, M ^a   Nassar, A ^a   Hamidieh, A A ^b   Kharfan Dabaja, M ^c   Othman, T B ^d   Elhaddad, A ^e   Seraihy, A ^a   Hussain, F ^a   Alimoghaddam, K ^b   Ladeb, S ^d   Fahmy, O ^e   Bazarbachi, A ^c   Mohamed, S Y ^a   Bakr, M ^a   Korthof, E ^f   Aljurf, M ^a   Ghavamzadeh, A ^b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^d CENTRE NATIONAL DE GREFFE DE MOELLE OSSEUSE   (Tunisia)

^e CAIRO UNIVERSITY   (Egypt)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CBT; DKC; EMRO; Hematopoietic SCT; MUD; Trends

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW DEPRESSION; CAUSE OF DEATH; CD34 SELECTION; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DYSKERATOSIS CONGENITA; ENGRAFTMENT; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INDUCTION CHEMOTHERAPY; LOW DRUG DOSE; MALE; MORBIDITY; MORTALITY; MYELOABLATIVE CONDITIONING; PARAAORTIC LYMPH NODE; PRESCHOOL CHILD; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SCHOOL CHILD; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; BONE MARROW DISEASES; CHILD; CHILD, PRESCHOOL; DYSKERATOSIS CONGENITA; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84883742527     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.35     Document Type: Article

References (35)

1. Zinsser F. Atrophia cutis reticularis cum pigmentations, dystrophia unguium et leukoplakis oris (Poikioodermia atrophicans vascularis Jacobi.). Ikonogr Dermatol 1910; 5: 219-223.
2. Savage SA. Dyskeratosis Congenita. In: Pagon RA, Bird TD, Dolan CR, Stephens K (eds). Gene Reviews [Internet]. University of Washington: Seattle, WA, USA, 1993-2009.
3. Savage SA, Alter BP. Dyskeratosis congenita. Hematol Oncol Clin North Am 2009; 23: 215-231.
4. Kirwan M, Dokal I. Dyskeratosis congenita, stem cells and telomeres. Biochim Biophys Acta 2009; 1792: 371-379.
5. Auluck A. Dyskeratosis congenita. Report of a case with literature review. Med Oral Patol Oral Cir Bucal 2007; 12: E369-E373.
6. Knight SW, Vulliamy TJ, Morgan B, Devriendt K, Mason PJ, Dokal I. Identification of novel DKC1 mutations in patients with dyskeratosis congenita: implications for pathophysiology and diagnosis. Hum Genet 2001; 108: 299-303.
7. Nishio N, Kojima S. Recent progress in dyskeratosis congenita. Int J Hematol 2010; 92: 419-424.
8. De la Fuente J, Dokal I. Dyskeratosis congenita: advances in the understanding of the telomerase defect and the role of stem cell transplantation. Pediatr Transplant 2007; 11: 584-594.
9. Tolar J, Orchard PJ, Miller JS, MacMillan ML, Wagner JE, Alter BP et al. Dyskeratosis congenita: low regimen-related toxicity following hematopoietic cell transplantation (HCT) using a reduced intensity conditioning regimen. Blood 2007; 110: 2005.
10. Dror Y, Freedman MH, Leaker M, Verbeek J, Armstrong CA, Saunders FE et al. Low-intensity hematopoietic stem-cell transplantation across human leucocyte antigen barriers in dyskeratosis congenita. Bone Marrow Transplant 2003; 31: 847-850.
11. Berthou C, Devergie A, D'Agay MF, Sonsino E, Scrobohaci ML, Loirat C et al. Late vascular complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol 1991; 79: 335-336.
12. Dietz AC, Orchard PJ, Baker KS, Giller RH, Savage SA, Alter BP et al. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. Bone Marrow Transplant 2011; 46: 98-104.
13. Ghavamzadeh A, Alimoghadam K, Nasseri P, Jahani M, Khodabandeh A, Ghahremani G. Correction of bone marrow failure in dyskeratosis congenita by bone marrow transplantation. Bone Marrow Transplant 1999; 23: 299-301.
14. Kharfan-Dabaja MA, Otrock ZK, Bacigalupo A, Mahfouz RA, Geara F, Bazarbachi A. A reduced intensity conditioning regimen of fludarabine, cyclophosphamide, antithymocyte globulin, plus 2 Gy TBI facilitates successful hematopoietic cell engraftment in an adult with dyskeratosis congenita. Bone Marrow Transplant 2012; 47: 1254-1255.
15. Ayas M, Al-Musa A, Al-Jefri A, Al-Seraihi A, Al-Mahr M, Rifai S et al. Allogeneic stem cell transplantation in a patient with dyskeratosis congenita after conditioning with low-dose cyclophosphamide and anti-thymocyte globulin. Pediatr Blood Cancer 2007; 49: 103-104.
16. Fogarty PF, Yamaguchi H, Wiestner A, Baerlocher GM, Sloand E, Zeng WS et al. Late presentation of dyskeratosis congenita as apparently acquired aplastic anemia due to mutations in telomerase RNA. Lancet 2003; 362: 1628-1630.
17. Dokal I, Luzzatto L. Dyskeratosis congenita is a chromosomal instability disorder. Leuk Lymphoma 1994; 15: 1-7.
18. Rocha V, Devergie A, Socié G, Ribaud P, Espérou H, Parquet N et al. Unusual complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol 1998; 103: 243-248.
19. Savage SA, Dokal I, Armanios M, Aubert G, Cowen EW, Domingo DL et al. Dyskeratosis congenita: the first NIH clinical research workshop. Pediatr Blood Cancer 2009; 53: 520-523.
20. Brazzola P, Duval M, Fournet JC, Gauvin F, Dalle JH, Champagne MA et al. Fatal diffuse capillaritis after haematopoietic stem cell transplantation for dyskeratosis congenita despite low-intensity conditioningreg regimen. Bone Marrow Transplant 2005; 36: 1103-1105.
21. Amarasinghe K, Dalley C, Dokal I, Laurie A, Gupta V, Marsh J. Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan. Bone Marrow Transplant 2007; 40: 913-914.
22. Yabe M, Yabe H, Hattori K, Morimoto T, Hinohara T, Takakura I et al. Fatal interstitial pulmonary disease in a patient with dyskeratosis congenita after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 389-392.
23. Langston AA, Sanders JE, Deeg HJ, Crawford SW, Anasetti C, Sullivan KM et al. Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita. Br J Haematol 1996; 92: 758-765.
24. Bizzetto R, Bonfim C, Rocha V, Socié G, Locatelli F, Chan K et al. Eurocord and SAAWP from EBMT. Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia. Haematologica 2011; 96: 134-141.
25. Dokal I, Manning R, Laffan M. Elevated levels and multimer pattern of von Willebrand factor in patients with dyskeratosis congenita. Br J Haematol 1995; 89: 33.
26. Amrolia P, Gaspar HB, Hassan A, Webb D, Jones A, Sturt N et al. Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood 2000; 96: 1239-1246.
27. Gungor T, Corbacioglu S, Storb R, Seger RA. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for treatment of dyskeratosis congenita. Bone Marrow Transplant 2003; 31: 407-410.
28. Paul SR, Perez-Atayde A, Williams DA. Interstitial pulmonary disease associated with dyskeratosis congenita. Am J Pediatr Hematol/Oncol 1992; 14: 89-92.
29. Utz JP, Ryu JH, Myers JL, Michels VV. Usual interstitial pneumonia complicating dyskeratosis congenita. Mayo Clin Proc 2005; 80: 817-821.
30. Alter BP, Giri N, Savage SA, Peters JA, Loud JT, Leathwood L et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol 2010; 150: 179-188.
31. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis 2010; 31: 9-18.
32. Shaw PH, Haut PR, Olszewski M, Kletzel M. Hematopoietic stem-cell transplantation using unrelated cord-blood versus matched sibling marrow in pediatric bone marrow failure syndrome: one center's experience. Pediatr Transplant 1999; 3: 315-321.
33. Velazquez I, Alter BP. Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am J Hematol 2004; 77: 257-267.
34. Giri N, Pitel PA, Green D, Alter BP. Splenic peliosis and rupture in patients with dyskeratosis congenita on androgens and granulocyte colony-stimulating factor. Br J Haematol 2007; 138: 815-817.
35. Vuong LG, Hemmati PG, Neuburger S, Terwey TH, Vulliamy T, Dokal I et al. Reduced-intensity conditioning using fludarabine and antithymocyte globulin alone allows stable engraftment in a patient with dyskeratosis congenita. Acta Haematol 2010; 124: 200-203.